Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,529.50
Bid: 1,531.50
Ask: 1,532.00
Change: 3.50 (0.23%)
Spread: 0.50 (0.033%)
Open: 1,537.00
High: 1,541.50
Low: 1,523.00
Prev. Close: 1,526.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-JD Sports leads FTSE 100 higher, rate cut hopes support

Tue, 10th Sep 2019 09:46

* FTSE 100 up 0.4%, FTSE 250 up 0.3%

* JD Sports hits life high after profit rise

* Galliford jumps on deal talks

* 888 skids as earnings hit by higher tax, Brexit-related
expenses
(Adds new items, analyst comments, updates to closing prices)

By Muvija M and Shashwat Awasthi

Sept 10 (Reuters) - London's FTSE 100 overcame early losses
to close higher on Tuesday as hopes of imminent interest rate
cuts from major central banks buoyed sentiment, while JD Sports
jumped to an all-time high on upbeat results.

The blue-chip index added 0.4%, with JD Sports
gaining 8.8% after its gym clothing and premium-branded
fashion helped it post higher profit and offset UK retail sector
gloom.

The FTSE 250 rose 0.3%, helped in part by a nearly
13% surge in Cairn Energy as strong half-year results
led to a production target upgrade.

In a sign of ongoing rotation, investors dumped defensive
shares and bought stocks of sectors that have underperformed
this year, helping an index of banks climb 2.4% for
its best day since January.

Shares of Lloyds and Barclays rose 4.3%
and 4.9%, respectively, while healthcare stocks GlaxoSmithKline
and AstraZeneca shed more than 2% each.

UK markets also looked past disappointing data from China
overnight that had added to fears of a global recession.

Speculation that the European Central Bank will cut interest
rates this week and that the U.S. Federal Reserve will follow
suit later this month in the face of slowing economic growth
helped stoke some risk appetite.

"Seeing as the ECB are tipped to go down the path of an
interest rate cut, stocks are likely to be buoyant between now
and the announcement," CMC Markets analyst David Madden said.

Oil heavyweights Shell and BP were the
biggest boosts to the main index as they tracked a rise in crude
prices on hopes that OPEC and other oil-producing countries may
agree to extend output cuts to prop up prices.

Mid-cap builder Galliford Try advanced 8% after it
restarted preliminary talks to sell its residential housing
businesses to Bovis Homes.

Bovis, whose shares dropped 3.5%, nudged up its proposed
offer and included a cash element, which Markets.com analyst
Neil Wilson said would be "a welcome injection for the newly
reorganised Galliford construction division."

Among small-caps, online gambling firm 888 Holdings
slumped 8.6%, its worst day in almost a year, after results
showed a hit to earnings from a rise in online gaming taxes and
administrative expenses due to Brexit preparations.
(Reporting by Muvija M in Bengaluru; Editing by Arun Koyyur and
Dan Grebler)

More News
23 Jun 2023 08:52

LONDON MARKET OPEN: Stocks down after BoE; GSK up on Zantac settlement

(Alliance News) - Stock prices in London opened lower on Friday, as rising interest rates weighed on housebuilding stocks in the FTSE 100.

Read more
23 Jun 2023 08:29

GSK reaches settlement in Goetz Zantac lawsuit

(Sharecast News) - GSK updated the market on the litigation regarding the now-discontinued heartburn drug ranitidine, or 'Zantac', on Friday.

Read more
23 Jun 2023 08:23

TOP NEWS: GSK reaches settlement in California Zantac lawsuit

(Alliance News) - GSK PLC on Friday said a Zantac trial set to begin next month in California has been dismissed after it reached a confidential settlement.

Read more
23 Jun 2023 08:19

Europe open: Stocks on the defensive after weak PMIs, euro awalloped

(Sharecast News) - Stocks on the Continent were trading on the back foot following the release of much weaker than expected readings for euro area factory and services activity.

Read more
23 Jun 2023 07:58

LONDON BRIEFING: GSK settles Zantac litigation in California

(Alliance News) - Stocks in London are set to open in the red on Friday, as risk sentiment across the globe is damped by hawkish central banks.

Read more
23 Jun 2023 07:42

European stocks head for worst week since March

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at .

EUROPEAN STOCKS HEAD FOR WORST WEEK SINCE MARCH (0638 GMT)

Read more
22 Jun 2023 09:26

GSK says Arexvy recommended in over 60s by US CDC committee

(Alliance News) - GSK PLC on Thursday said the US Centers for Disease Control & Prevention's Advisory Committee on Immunization Practices has voted to recommend the firm's Arexvy jab in adults aged 60 and older.

Read more
22 Jun 2023 07:51

US CDC votes to recommend GSK's Arexvy against RSV

(Sharecast News) - America's public health watchdog endorsed GSK's Arexvy for use against Respiratory Syncytial Virus in adults over 60.

Read more
21 Jun 2023 23:10

US CDC advisers recommend older adults may receive Pfizer, GSK shots for RSV

June 21 (Reuters) - A panel of advisers to the U.S. Centers for Disease Control and Prevention (CDC) on Wednesday recommended that new vaccines from Pfizer and GSK to prevent severe respiratory syncytial virus (RSV) infections be available to older adults in the U.S. but stopped short of saying all of them should get the shots.

Read more
21 Jun 2023 22:10

US CDC advisers back use of GSK, Pfizer RSV vaccines in older adults

June 21 (Reuters) - A panel of advisers to the U.S. Centers for Disease Control and Prevention (CDC) on Wednesday recommended that adults aged 60 and above may receive the recently approved vaccines from Pfizer and GSK to prevent severe respiratory syncytial virus (RSV) infections. (Reporting by Raghav Mahobe in Bengaluru and Michael Erman in New York; Editing by Leslie Adler)

Read more
21 Jun 2023 11:00

US CDC advisers weigh use of GSK, Pfizer RSV vaccines in older adults

June 21 (Reuters) - A panel of advisers to the U.S. Centers for Disease Control and Prevention (CDC) on Wednesday will vote on whether to recommend the use of recently approved vaccines from Pfizer and GSK to prevent severe respiratory syncytial virus (RSV) infections in older adults.

Read more
21 Jun 2023 09:19

GSK unveils positive trial results for vaccine against RSV

(Sharecast News) - GSK unveiled unveiled successful third phase clinical trial results for its Arexvy vaccine against respiratory syncytial virus in older adults.

Read more
21 Jun 2023 08:20

TOP NEWS: GSK reports positive data for RSV Arexvy vaccine

(Alliance News) - GSK PLC on Wednesday reported positive data for Arexvy, its respiratory syncytial virus vaccine for older adults.

Read more
20 Jun 2023 17:20

Miners, oil drag London stocks lower after modest China rate cut

Miners down as metal prices fall on strong dollar, China worries

*

Read more
20 Jun 2023 08:33

Lab crunch: British science has nowhere to go

OXFORD, England, June 20 (Reuters) - For Ros Deegan, the thrill of raising $100 million to expand a biotech firm among the dreaming spires of Oxford was soon tempered: unable to find a bigger laboratory, she routinely had to work at home.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.